Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
BIO-TECHNE Corp reported revenue of $1.22 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), down 0.4% from fiscal 2025. Net income was $182 million and diluted earnings per share $1.16.
In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $300 million, up 4.6% from a year earlier.
Figures from BIO-TECHNE Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.
Fiscal 2026 against fiscal 2025; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Segment | Revenue | Share | Change |
|---|---|---|---|
| Protein Sciences | $874.6M | 72% | +0.5% |
| Diagnostics and Spatial Biology | $336.4M | 28% | −2.9% |
| Not allocated to a line | $4.05M | 0.3% | — |
BIO-TECHNE Corp beside the other S&P 500 members in Life Sciences Tools & Services, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| Bio-TechneTECH | — | −0.1% | +18.6% | — | — | — |
| $163.0B | +0.4% | +6.2% | +5.5% | 16.9% | 37.6 | |
| $48.72B | +0.5% | +14.8% | +8.6% | 19.5% | 33.8 | |
| $43.52B | −2.2% | +20.0% | +8.8% | 8.1% | 31.2 | |
| IlluminaILMN | $30.43B | −4.2% | +65.3% | +5.8% | 19.7% | 34.0 |
| $16.06B | −0.8% | +97.1% | −1.2% | 1.0% | 399.6 | |
| — | +0.5% | +20.1% | — | — | — |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.
| Revenue | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Protein Sciences | $832.3M | $845.7M+1.6% | $830.9M−1.8% | $870.2M+4.7% | $874.6M+0.5% |
| Diagnostics and Spatial Biology | $274.8M | $292.6M+6.5% | $326.4M+11.5% | $346.3M+6.1% | $336.4M−2.9% |
| Not allocated to a line | — | — | — | — | $4.05M |
| Total revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Revenue | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Consumables | $890.9M | $917.7M+3.0% | $928.2M+1.1% | $972.3M+4.8% | $985.1M+1.3% |
| Instruments | $120.8M | $112.1M−7.2% | $108.3M−3.4% | $112.1M+3.5% | $110.6M−1.3% |
| Services | $71.99M | $85.78M+19.2% | $99.27M+15.7% | $111.6M+12.4% | $94.30M−15.5% |
| Royalty | $21.98M | $21.10M−4.0% | $23.34M+10.6% | $23.69M+1.5% | $24.99M+5.5% |
| Total revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Revenue | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| United States | $614.1M | $642.5M+4.6% | $657.7M+2.4% | $683.2M+3.9% | $635.4M−7.0% |
| EMEA, excluding United Kingdom | $219.1M | $220.2M+0.5% | $241.4M+9.6% | $266.3M+10.3% | $294.2M+10.5% |
| China | $112.4M | $113.9M+1.3% | $99.47M−12.6% | $100.5M+1.0% | $104.1M+3.6% |
| APAC, excluding Greater China | $76.14M | $73.19M−3.9% | $73.90M+1.0% | $77.26M+4.5% | $85.81M+11.1% |
| United Kingdom | $48.64M | $49.46M+1.7% | $50.01M+1.1% | $54.83M+9.6% | $56.28M+2.7% |
| Rest of World | $35.22M | $37.49M+6.4% | $36.50M−2.7% | $37.55M+2.9% | $39.28M+4.6% |
| Total revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
Fiscal years, the latest ending 30 Jun 2026. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Revenue growth | +12.8% | +14.2% | +11.0% | +3.5% | +26.0% | +18.7% | +2.8% | +2.0% | +5.2% | −0.4% |
| Gross profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Operating income | $120.6M | $136.2M | $146.7M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Net income | $76.09M | $126.2M | $96.07M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.36M | $181.8M |
| Diluted EPS | $0.51 | $0.83 | $0.62 | $1.45 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Gross margin | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating margin | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net margin | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| Period | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $143.7M | $170.4M | $181.6M | $205.2M | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M | $292.1M |
| Capital expenditure | $15.18M | $20.93M | $25.41M | $51.74M | $44.30M | $44.91M | $38.24M | $62.88M | $31.01M | $28.85M |
| Free cash flow | $128.5M | $149.4M | $156.2M | $153.5M | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
| Period | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $91.61M | $122.0M | $100.9M | $146.6M | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Total debt | $343.8M | $339.0M | $505.2M | $433.5M | $420.6M | $326.0M | $455.0M | $419.5M | $444.1M | $289.1M |
| Shareholders' equity | $949.6M | $1.08B | $1.17B | $1.38B | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
| Diluted shares | 150M | 152M | 156M | 158M | 162M | 164M | 162M | 161M | 160M | 157M |
| Dividends per share | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.80 | $0.32 | $0.32 | $0.32 | $0.32 |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $297.0M | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M | $321.2M | $299.7M |
| Revenue, year on year | +9.0% | +4.2% | +3.5% | −1.0% | −0.4% | −1.5% | +1.3% | +4.6% |
| Gross margin | 65.3% | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% | 65.8% | 65.6% |
| Operating income | $47.42M | $38.71M | −$23.86M | $47.66M | $54.46M | $75.50M | $74.28M | $36.60M |
| Net income | $34.89M | $22.59M | −$17.70M | $38.18M | $38.00M | $51.04M | $54.64M | $28.29M |
| Diluted EPS | $0.22 | $0.14 | −$0.11 | $0.24 | $0.24 | $0.32 | $0.35 | $0.18 |
| Free cash flow | $77.53M | $31.00M | $93.31M | $22.22M | $76.49M | $77.58M | $86.94M | $67.20M |
The operating figures BIO-TECHNE Corp reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| Product and Services revenue | $285.2M | quarter to 30 Sep 2026 | up 1.5% | |
| Consumables revenue | $237.3M | quarter to 30 Sep 2026 | up 2.4% | |
| Instruments revenue | $25.5M | quarter to 30 Sep 2026 | up 16.8% | |
| Services revenue | $22.5M | quarter to 30 Sep 2026 | down 18.3% | |
| Royalty revenue | $14.5M | quarter to 30 Sep 2026 | up 156.7% | |
| Protein Sciences revenue | $219.7M | quarter to 30 Sep 2026 | up 8.7% | |
| Diagnostics and Spatial Biology revenue | $80.2M | quarter to 30 Sep 2026 | up 0.9% | |
| United States revenue | $152.7M | quarter to 30 Sep 2026 | down 1.7% | |
| EMEA, excluding United Kingdom revenue | $73.9M | quarter to 30 Sep 2026 | up 13.5% | |
| China revenue | $28.9M | quarter to 30 Sep 2026 | up 16.6% | |
| APAC, excluding Greater China revenue | $22.5M | quarter to 30 Sep 2026 | up 17.3% | |
| United Kingdom revenue | $13.7M | quarter to 30 Sep 2026 | up 4.0% | |
| Rest of World revenue | $8.1M | quarter to 30 Sep 2026 | down 11.0% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$1.22 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), as reported in its annual report.
$182 million for fiscal year 2026 (the twelve months to 30 Jun 2026).
$1.16 for fiscal year 2026 (the twelve months to 30 Jun 2026).
65.8% for fiscal year 2026 (the twelve months to 30 Jun 2026): gross profit divided by revenue.
20.7% for fiscal year 2026 (the twelve months to 30 Jun 2026): operating income divided by revenue.
$263 million for fiscal year 2026 (the twelve months to 30 Jun 2026): operating cash flow less capital expenditure.
In fiscal 2026, by segment: Protein Sciences $874.6M (72%), Diagnostics and Spatial Biology $336.4M (28%), out of $1.22B in all, as stated in its annual report.
In the terminal